$0.92
+0.05 (+6.23%)
Open$0.89
Previous Close$0.87
Day High$0.92
Day Low$0.88
52W High$2.95
52W Low$0.60
Volume—
Avg Volume46.9K
Market Cap3.53M
P/E Ratio—
EPS$-22.83
SectorBiotechnology
Analyst Ratings
Strong Sell
8 analysts
Price Target
+2,194.9% upside
Current
$0.92
$0.92
Target
$21.09
$21.09
$14.27
$21.09 avg
$34.90
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.52M | 557.3K | 516.3K |
| Net Income | -151,194,676 | 76.7K | 85.4K |
| Profit Margin | -1,132.4% | 13.8% | 16.5% |
| EBITDA | -114,761,619 | 122.1K | 108.8K |
| Free Cash Flow | — | 55.8K | 59.0K |
| Rev Growth | +166.9% | +2.4% | +15.9% |
| Debt/Equity | 0.21 | 0.52 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |